Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
In our 30+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
Calling attention to a podcast from Wilmer Eye – Diagnosis Glaucoma. Drs. Mona Kaleem and Harry Quigley talk with Dr. Gary Novack about the Drug Development Process for new pharmacological treatments for glaucoma. In episode 43, discussed are the development and FDA approval process of eye drop medications for glaucoma.
Dr. Novack was selected to be a fellow of the Association for Ocular Pharmacology and Therapeutics. The Association for Ocular Pharmacology and Therapeutics is a global organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic applications. Fellows of AOPT are nominated by their peers
Dr. Novack gave a lecture at the Kellogg Eye Center of the School of Medicine at the University of Michigan. The topic was “Contaminated Eye Drops: What is going on”? He described the ongoing issue with contamination and infection, what to do for patients, and the impact of this issue